Rallybio Corp 10-Q — AI Bull & Bear Analysis

Rallybio's Q1 2026 filing reveals a company at a critical crossroads, balancing a strengthened short-term cash position against long-term clinical uncertainty. The termination of the Candid merger was a double-edged sword: while it resulted in a $50 million cash windfall, it also removed a definitive exit path, leaving the company to seek a new buyer or partner. The narrowing of net losses to $8.28 million reflects a strategic decision to kill non-core programs like RLYB212, effectively concentrating all corporate risk and reward into RLYB116. Ultimately, the investment thesis now hinges on the timing of a strategic transaction. The company has sufficient liquidity to operate for at least 12 months, but the window for a premium acquisition is narrow. If Rallybio cannot leverage its Phase 1 data to secure a partner or buyer shortly, it will likely face a liquidity crunch as it enters the expensive later stages of clinical development. The filing confirms a shift in identity from a diversified biotech to a specialized vehicle for a single high-potential asset.